If the experimental treatment was found safe during phase 1 clinical trials, it will be given the green light to move forward to phase 2 clinical trials. Whereas phase 1 clinical trials focus on whether the experimental drug is safe, phase 2 clinical trials focus on whether the experimental drug is effective against its targeted condition. A phase 2 clinical trial is usually larger than a phase 1 clinical trial. Because larger numbers of people are taking part in a phase 2 clinical trial, more side effects might be detected that were not seen in a phase 1 clinical trial. These new side effects will be evaluated along with other endpoints in a phase 2 clinical trial. If new side effects detected are not that bad, and the treatment is shown to be effective, then the treatment will be given the green light to move forward with a phase 3 clinical trial.